IFF Achieves Key 2020 Sustainability Goals
13.5.2021 23:15:00 EEST | Business Wire | Press release
IFF (NYSE:IFF) today announced the achievement of key 2020 sustainability goals that were set at the launch of the Company’s sustainability program in 2010. During that time, IFF met and surpassed its original intensity-based targets for three environmental goals, resulting in a reduction in its greenhouse gas (GHG) emissions, water withdrawal and hazardous waste generation per metric ton of production by -42.6%, -67.1% and -41% below 2010 levels, respectively. IFF has also achieved its 2020 goal to have 100% of the palm oil used in its products be certified according to the Roundtable on Sustainable Palm Oil (RSPO) Mass Balance Supply Chain Model.
These and other milestones are captured in its latest Sustainability Report, “For a Better World,” which is published today. The title references the Company’s purpose – Applying science and creativity for a better world – a clear and bold aspiration that inspires everyone at IFF to push past traditional boundaries and to be a force for a better and more sustainable future.
Andreas Fibig, IFF Chairman and CEO, said: “Although 2020 was a year unlike any we could have predicted, I am proud to say that IFF rose to the challenges we faced and remained steadfast in our commitments to people and planet – further strengthening our sustainability leadership position. As pleased as we are with our results, the solemnity of the urgent challenges that remain – from the climate emergency and nature loss to mounting inequality – compels us to do more, to do better. As we work toward a better world with the continued support of our employees, customers, suppliers and other partners, we look forward to building on our successes in 2020 and achieving even more ambitious environmental, social and governance (ESG) targets in the future.”
In addition to highlighting progress against IFF’s 2020 environmental goals, the report also covers the Company’s achievements throughout the business in leveraging sustainable practices within its global footprint. For example:
- Externally recognized for sustainability leadership, including being named to the Dow Jones Sustainability Indices, FTSE4Good Index Series, Euronext Vigeo World 120 Index and CDP A list, as well as receiving the EcoVadis platinum sustainability rating
- Continued its commitment to climate action by advancing on its Science Based Target to reduce absolute GHG emissions by 19.7% since 2015; powering 52% of its operations’ electricity requirements with renewable energy; and reporting for the first time in alignment with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD)
- Expanded safety culture and training, resulting in a reduction in its lost time incident rate of 46% from the prior year
- Launched industry-leading blockchain technology as a tool for ensuring ingredient traceability in the vanilla supply chain in Madagascar
- Further embedded its commitment to circular design across its business, including by launching the Upcycled Extracts Collection, an ingredients portfolio made from several types of side-streams from its own processing that would otherwise be discarded
- Strengthened its commitment to diversity, equity & inclusion and was the first company to earn Economic Dividend for Gender Equality (EDGE) Move level certification globally
Dr. Greg Yep, IFF’s Chief Research & Development, Global Integrated Solutions and Sustainability Officer, said, “Looking back over ten years of sustainability at IFF, we are thrilled with what we have been able to achieve. Following the merger with DuPont Nutrition & Biosciences, the decade ahead not only marks the next phase of IFF’s sustainability journey, but also represents a pivotal window of opportunity. By focusing on sustainable innovation, circular design and integrated solutions, we look forward to leveraging our newly expanded capabilities to help address the world’s greatest sustainable development challenges.”
To read IFF’s 2020 Sustainability Report, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.
Webcast
A live webcast to discuss the Company’s 2020 sustainability results and 2021 outlook will be held on May 20, 2021 at 9:00 a.m. ET. Mr. Fibig and Dr. Yep will be joined by Chief Investor Relations & Communications Officer Michael DeVeau; and Vice President, Global Sustainability & EHS Kip Cleverley, who will share updates on IFF’s key ESG metrics, goals and sustainability strategy. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com.
Investors and analysts are invited to participate by phone by calling 1-866-342-8591 from the United States and 1-203-518-9713 from other locations. The access code for the conference call is IFF0520 and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005952/en/
Contact information
Michael DeVeau
Chief Investor Relations & Communications Officer
212.708.7164
Michael.DeVeau@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
